@entity1200 ( @entity1200 ) is used successfully in the treatment of @entity573 , with dose-dependent rapid resolution of symptoms such as @entity221 and @entity146 and a decrease in ESR, WBCs, and platelets. The mode of action of @entity1200 in reducing this inflammatory response is not clearly understood. Recently anticytokine antibodies in @entity1200 have been demonstrated. Serum levels of proinflammatory cytokines have been shown to be elevated in @entity1 with @entity573 . The cytokine @entity650 ( @entity650 ) is involved in the de novo production of acute-phase proteins by hepatocytes and cause @entity1148 and @entity221 in response to tissue injury. @entity1 receiving parenteral recombinant @entity1 @entity650 have dose-dependently experienced @entity221 , malaise, chills, and acute-phase reaction. With high @entity650 concentrations, @entity149 has also been reported and @entity650 has been thought to mediate endothelial damage. We evaluated the response of stimulated blood cells of 12 normal @entity1 to @entity1200 in the release of the cytokines @entity650 , @entity687 , @entity310 . and @entity650 receptor (sIL-6R). The levels of cytokines @entity650 , @entity687 , and @entity310 (but not sIL-6R) in peripheral blood induced by stimulation with @entity558 were markedly reduced (P < 0.008) within 3 hr when incubated with @entity1200 compared to without @entity1200 . Thus we demonstrated that cells of normal @entity1 respond to @entity1200 in vitro by reducing cytokines such as @entity687 , @entity310 , and @entity650 without affecting the level of receptor sIL-6R during an acute inflammatory response. We also found significantly higher @entity650 levels in @entity1 with @entity573 compared to @entity1 with blood culture-negative febrile illnesses. In five @entity1 with @entity573 we measured serum @entity650 before and after @entity1200 and assessed the clinical response to @entity1200 therapy. Therapy with @entity1200 was followed by a rapid resolution of symptoms in @entity573 , with a significant decrease in serum @entity650 . The attenuation of proinflammatory cytokine responses, especially @entity650 , following infusions of @entity1200 may play an integral role in the rapid resolution of symptoms and decrease in the acute-phase proteins in @entity1 with @entity573 . Cells of normal @entity1 were found to respond to the @entity1200 in a manner similar to that of the Kawasaki @entity1 .

Cytokine modulation with immune gamma-globulin in peripheral blood of normal XXXX and its implications in @entity573 treatment.

@entity1 :: ('9606', 'Species') :: ['children', 'Patients', 'human', 'patients'] @entity650 :: ('3569', 'Gene') :: ['IL-6', 'interleukin-6'] @entity558 :: ('MESH:C536528', 'Disease') :: ['LPS'] @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocytosis'] @entity573 :: ('MESH:C537014', 'Disease') :: ['Kawasaki disease'] @entity146 :: ('MESH:D001523', 'Disease') :: ['irritability'] @entity310 :: ('7124', 'Gene') :: ['TNF-alpha'] @entity149 :: ('MESH:D002493', 'Disease') :: ['central nervous system toxicity'] @entity1200 :: ('MESH:D007154', 'Disease') :: ['Intravenous immune gamma-globulin', 'IVIG'] @entity687 :: ('3576', 'Gene') :: ['IL-8'] @entity221 :: ('MESH:D005334', 'Disease') :: ['fever']
@entity1 :: (9606,Species) :: ['children']
